A recent study of the abortion pill, representing over 60% of all abortions in the U.S., found it sent more than 1 in 10 women to the emergency room with serious complications. Robert F Kennedy Jr. at Health and Human Services and Dr. Marty Makary, head of the FDA, noted that due to recent revelations, the drug is undergoing a “complete review” for safety.
If so, why, on October 1, did the FDA approve another generic version of what many have characterized as a “chemical coat hanger”? Is this a bureaucratic blunder or something more insidious? Is it acceptable within the FDA rank and file to trade women’s lives in exchange for cheap abortion?
A dollar-for-dollar match allows you to save 2 times more women and babies in America’s abortion capital of New York. Make your tax-deductible donation at 2x.life today.
